Skip to main content
. Author manuscript; available in PMC: 2022 Apr 13.
Published in final edited form as: J Med Chem. 2020 Oct 29;63(21):12957–12977. doi: 10.1021/acs.jmedchem.0c01398

Figure 8.

Figure 8.

In vivo efficacies in an Ru337 PDX subcutaneous mouse tumor model of compound 27 as monotherapy and in combination with dual TORC inhibitor TAK-228. Compound 27 (neutral compound) was administered orally twice daily at 100 mg/kg in an 0.5% aqueous methylcellulose vehicle; TAK-228 was dosed orally once daily at 1 mg/kg in an 0.5% aqueous methylcellulose, 5% sucrose vehicle. Both compounds were dosed on a schedule of 5 days on / 2 days off,49 and there were 8 animals per group. (a) Tumor volumes plotted as means ± standard deviation; (b) Average % bodyweights relative to day 0 plotted as means ± standard deviation.